November 18, 2026
Health news, explained with evidence
LIVE

Placental Stem Cell Therapy Shows Potential in Healing Chronic Diabetic Ulcers

🧠 AI Analysis 2 min read 👁 14

A first-in-human pilot study found that placental-derived stem cells successfully closed chronic diabetic foot wounds and improved nerve sensation in all participants.

Placental Stem Cell Therapy Shows Potential in Healing Chronic Diabetic Ulcers🧠AI Analysis

Photo: Medical Xpress

Key points

  • All 10 participants in the pilot study experienced total wound closure within six months of treatment.
  • The therapy used stem cells derived from donated placental tissue, which was injected around the ulcer site.
  • Most participants regained critical protective sensation in their feet, potentially reducing the risk of future injuries.

Placental Cell Therapy for Diabetic Wounds

Researchers at the Wake Forest Institute for Regenerative Medicine (WFIRM) have successfully completed a pilot study using an experimental cell therapy to treat chronic diabetic foot ulcers. The first-in-human trial involved 10 adults in Nicaragua, aged 40 to 74, whose wounds had remained open for at least three months despite standard medical care. By the six-month mark, all 10 participants achieved complete wound closure, a significant milestone for a condition that is a leading cause of lower-limb amputations.

The investigational treatment utilized stem cells harvested from healthy placental tissue donated after childbirth. These cells, which are typically discarded, possess unique properties that may reduce inflammation and promote tissue repair. During the study, participants received a single injection of either 30 million, 40 million, or 60 million cells directly into and around the wound site. Researchers reported that all dosage levels were well tolerated, with no serious treatment-related adverse events observed during the 12-month follow-up period.

In addition to wound healing, the study measured improvements in peripheral neuropathy, or nerve damage. Tests indicated that participants regained the ability to feel light touch and vibrations. By the end of the year-long monitoring period, nine out of ten patients had recovered what is termed "normal protective sensation," which allows individuals to feel pressure or discomfort that signals potential injury. While sensation improved, the therapy's impact on blood flow was less definitive, showing inconsistent results across the group.

What to know: This was a small, uncontrolled safety study; larger clinical trials are necessary to confirm these findings and establish standardized dosing. Patients should continue to work closely with their healthcare providers to manage diabetes and monitor foot health.

Source Medical Xpress — medicalxpress.com/news/2026-11-cell-therapy-difficult-diabetic-foot.html ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.